ICIG completes acquisition of Sandoz site

By Melissa Fassbender

- Last updated on GMT

Sandoz will be re-named Corden BioChem GmbH. (Image: iStock)
Sandoz will be re-named Corden BioChem GmbH. (Image: iStock)

Related tags Metabolism

International Chemical Investors Group (ICIG) has completed its acquisition of Sandoz Industrial Products GmbH from Novartis Group.

The previously announced agreement between ICIG’s pharma platform, CordenPharma, and the Frankfurt-Höchst-based manufacturer of enzyme-based fermentation products and intermediates was established in February of this year.

The new site will expand the CordenPharma’s operations, specifically growing its enzymes-based manufacturing portfolio and antibiotics technology platform, adding new capabilities in microbial fermentation and enzymatic reactions.

As Outsourcing-Pharma.com reported​, the acquisition will establish CordenPharma as one of the major suppliers of 7-ACA to customers worldwide. Additionally, the company will use the material in-house for its anitbiotics value chain located in Latina, Itay.

Sandoz will maintain its operations associated with the CordenPharma Group, ICIG’s pharma platform, and will be re-named Corden BioChem GmbH.

Corden BioChem will be complementary to both ICIG’s pharma activities as well as to its fine chemicals activities within the WeylChem Group,​” the company commented in its announcement. “The site represents an important additional building block of fermentation-based production technology for ICIG​.”

Achim Riemann, ICIG Owner, told us that CordenBiochem has become part of the company's antibiotics platform within CordenPharma and "will be managed as a profit center like all other companies of the group using the services and Support functions of the group​." He added, "CordenPharma has the ambition to grow further and plans add on acquisitions in API and drug product manufacturing​."

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us

Products

View more

Webinars